TrialPath
Recruiting

Twiist Postmarket Surveillance Study for Type 1 Diabetes

NCT07356089 · Deka Research and Development
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Twiist Postmarket Surveillance Study in Adults and Youth With Type 1 Diabetes
About this study
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
Eligibility criteria
Inclusion Criteria: * Willing and able to provide informed consent (or a parent or other legally authorized representative) * Age ≥ 6 years old * Diagnosis of T1D * Currently using twiist AID system, with initiation of twiist within 90 days of enrollment * Willing to only use an insulin approved for the pump * Residing in United States * Willing to use twiist in accordance with the user manual * Willing to have the study use the twiist data and any information that has been provided to Sequel Medtech, LLC or customer support since twiist was started * Willing to complete surveys at the beginning of the study and then monthly for 12 months * Willing to be contacted if clarification or further information is needed for any events reported on a survey or to customer support * Willing to provide medical records or sign a record release for any hospitalizations * Has cell service or if not, will have access to WIFI at least once a week * For females, not pregnant or planning pregnancy in the next 12 months * Able to speak and read English * Able to obtain documentation of HbA1c result obtained within 6 months prior to twiist initiation Exclusion Criteria: * Any form of diabetes other than T1D * Receiving dialysis for end-stage renal disease
Study design
Enrollment target: 1875 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2025-12-09
Estimated completion: 2028-05-01
Last updated: 2026-01-21
Interventions
Device: twiist Automated Insulin Delivery System
Primary outcomes
  • • Severe hypoglycemia events (From enrollment to the end of participation at 12 months)
Sponsor
Deka Research and Development · industry
With: Jaeb Center for Health Research
All locations (1)
Jaeb Center for Health ResearchRecruiting
Tampa, Florida, United States
Twiist Postmarket Surveillance Study for Type 1 Diabetes · TrialPath